Suzuken achieved net sales of \u00a52.4866 trillion (up 3.6% YoY) and net income attributable to owners of the parent of \u00a538.136 billion (up 10.6%) for the fiscal year ending March 2026. Based on mid-term management plans, the company is promoting transformation of existing businesses and preparation for new businesses, aiming for continued growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"9987","jir_company_name":"Suzuken Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/9987-20260514-01.pdf","jir_short_summary":"Suzuken achieved net sales of \u00a52.4866 trillion (up 3.6% YoY) and net income attributable to owners of the parent of \u00a538.136 billion (up 10.6%) for the fiscal year ending March 2026. Based on mid-term management plans, the company is promoting transformation of existing businesses and preparation for new businesses, aiming for continued growth.","jir_summary":"### Performance Overview\nSuzuken recorded net sales of \u00a52.4866 trillion (up 3.6% YoY) and net income attributable to owners of the parent of \u00a538.136 billion (up 10.6%) for the fiscal year ending March 2026. While expanding due to growth in the pharmaceutical market and contributions from new drugs, operating income decreased due to rising costs and procurement prices. The pharmaceutical wholesale segment remains primary, with efforts to expand specialty drug distribution and strengthen logistics infrastructure. Moving forward, the company will continue to transform existing businesses and develop new ones in line with its mid-term management plan to achieve sustainable growth.\n\n### Future Outlook and Shareholder Returns\nFor the fiscal year ending March 2027, earnings are projected to be net sales of \u00a52.563 trillion (up 3.1% YoY) and net income of \u00a525 million (down 34.4%). The company will address environmental changes by promoting next-generation wholesale and reconfiguring its business portfolio. Shareholder returns are planned to include a dividend of \u00a5120 (interim \u00a560, final \u00a560), with a stock split also scheduled. Key initiatives in the mid-term management plan include strengthening business functions and enhancing management foundation, with a focus on sustainable growth and increasing corporate value.","jir_financial_highlights":"Net Sales: \u00a52,486.6 billion (up 3.6% YoY)\nNet Income Attributable to Owners of the Parent: \u00a538.136 billion (up 10.6% YoY)\nOperating Income: \u00a536.374 billion (down 2.0% YoY)","jir_category":"","jir_hashtags":"#Suzuken, #IRFinancialResults, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a52.4866 trillion (up 3.6% YoY)\nNet Income Attributable to Owners of the Parent: \u00a538.136 billion (up 10.6%)\nForecasted Net Sales for March 2027: \u00a52.563 trillion (up 3.1% YoY)","jir_meta_title":"\u3010Suzuken\u30112026 Financial Results\uff5cSales Exceed \u00a52.5 Trillion, Net Income Up 10%","jir_meta_description":"Suzuken achieved net sales of \u00a52.4866 trillion and net income of \u00a538.1 billion for the fiscal year ending March 2026. It will continue ongoing transformation and growth in line with its mid-term plan.","jir_og_title":"\u3010Suzuken\u30112026 Financial Results\uff5cSales of \u00a52.5 Trillion, 10% Increase in Net Income","jir_og_description":"Suzuken achieved sales exceeding \u00a52.5 trillion and a 10% increase in net income for the fiscal year ending March 2026. It will promote business transformation and growth based on its mid-term plan.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Sales Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2022\\\",\\\"2023\\\",\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[\\\"Unknown\\\",\\\"Unknown\\\",\\\"Unknown\\\",\\\"\u00a52.3999 trillion\\\",\\\"\u00a52.4866 trillion\\\"]}]}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2022\\\",\\\"2023\\\",\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[\\\"Unknown\\\",\\\"Unknown\\\",\\\"Unknown\\\",\\\"\u00a53.49 billion\\\",\\\"\u00a53.813 billion\\\"]}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment-wise Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Wholesale Business\\\",\\\"Healthcare Product Development Business\\\",\\\"Regional Medical and Care Support Business\\\",\\\"Specialty Pharmaceutical Distribution Contract Business\\\",\\\"Medical Related Services\\\"],\\\"datasets\\\":[{\\\"data\\\":[\\\"Unknown\\\",\\\"Unknown\\\",\\\"Unknown\\\",\\\"Unknown\\\",\\\"Unknown\\\"]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Sales\\\",\\\"Operating Income\\\",\\\"Net Income\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"2026\\\",\\\"data\\\":[\\\"Unknown\\\",\\\"Unknown\\\",\\\"Unknown\\\"]}]}}\"}]","ir_related_company":7932,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-50342","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n